Post by savzak on Jun 10, 2014 13:47:50 GMT -5
www.pharmamanufacturing.com/articles/2014/next-gen-biologics-market-worth-30b-by-2024/
From the article:
In the Pipeline
Visiongain forecasts that there will be at least five blockbuster next-generation biologics creating a market worth $1 billion by 2024 and that in the same period, revenues of the seven top brands including Adcetris, Kadcyla, Gazyva, Tresiba, Afrezza, Plegridy and Eloctate, are likely to bring in $10 billion, fueling even more development. “Next-generation biologics will address shortcomings in current therapies,” say visiongain, including inconvenient dosing and concerns over side effects.” Development trends say analysts include sustained release to help dose intervals and compliance, and reformulations for oral and topical administration.